secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0000950170-25-053944
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026
-------------------------------------------------------------------------------

- Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.
- FDA confirmed HS-NRE biomarker may reasonably predict clinical benefit and could support accelerated approval.
- BLA submission for TA-ERT anticipated in first half of 2026; fast-track, orphan, and rare pediatric designations granted.
- Cash and cash equivalents $38.8M as of Dec 31, 2024; expected cash runway through end of 2025.
- 42.2M shares outstanding, 21.4M reserved for warrants and equity as of Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/0000950170-25-053944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017025053944/sprb-20250415.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer